182 Effect of M0002, a Novel V2 Antagonist on Sodium Levels and Weight Gain Affected by Water Accumulation in Cirrhotic Patients With Ascites

Nevens, Frederik; Moreno, C Alvarez; Cools, Michael J.; Thielemans, Leen; Kerstens, René; Meulemans, A.L.

doi:10.1016/s0168-8278(09)60184-7

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, in one of the three studies, it was associated with an increased mortality 67 . Short‐term studies involving other vaptans, such as M0002 68 or tolvaptan, 69 have shown efficacy of these two vaptans in improving ascites. However, the study with M0002 only involved 15 patients for a total administration course of 2 weeks, while that using tolvaptan included 18 patients for a total of nine study days.…”

Section: Potential New Treatments For Ascitesmentioning

confidence: 94%

Management of ascites in cirrhosis

Wong

2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

Ascites is a common complication of liver cirrhosis associated with a poor prognosis. The treatment of ascites requires dietary sodium restriction and the judicious use of distal and loop diuretics, sequential at an earlier stage of ascites, and a combination at a later stage of ascites. The diagnosis of refractory ascites requires the demonstration of diuretic nonresponsiveness, despite dietary sodium restriction, or the presence of diuretic-related complications. Patients with refractory ascites require second-line treatments of repeat largevolume paracentesis (LVP) or the insertion of a transjugular intrahepatic portosystemic shunt (TIPS), and assessment for liver transplantation. Careful patient selection is paramount for TIPS to be successful as a treatment for ascites. Patients not suitable for TIPS insertion should receive LVP. The use of albumin as a volume expander is recommended for LVP of >5-6 L to prevent the development of circulatory dysfunction, although the clinical significance of post-paracentesis circulatory dysfunction is still debated. Significant mortality is still being observed in cirrhotic patients with ascites and relatively preserved liver and renal function, as indicated by a lower Model for End-Stage Liver Disease (MELD) score. It is proposed that patients with lower MELD scores and ascites should receive additional points in calculating their priority for liver transplantation. Potential new treatment options for ascites include the use of various vasoconstrictors, vasopressin V 2 receptor antagonists, or the insertion of a peritoneo-vesical shunt, all of which could possibly improve the management of ascites.

show abstract

Section: Potential New Treatments For Ascitesmentioning

confidence: 94%

Management of ascites in cirrhosis

Wong

2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…However, a longer-term study over a 52-week period in a larger cohort of cirrhotic patients with ascites was only able to show a trend towards a better control of ascites in terms of the time to the first paracentesis and the frequency of large volume paracentesis [79]. Short-term studies with other vaptans, such as M0002 [80] or tolvaptan [81], also showed efficacy in improving ascites. However, the study with M0002 only involved 15 patients for a total of vaptan administration of 2 weeks, while that using tolvaptan included 18 patients for a total of nine study days.…”

Section: Vasopressin V2 Receptor Antagonistsmentioning

confidence: 96%

Medical management of ascites

Leung¹

2011

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Interventions for chronic non-hypovolaemic hypotonic hyponatraemia

Nagler

Haller²,

Biesen

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

In people with chronic hyponatraemia, vasopressin receptor antagonists modestly raise serum sodium concentration at the cost of a 3% increased risk of it being rapid. To date there is very low certainty evidence for patient-important outcomes; the effects on mortality and health-related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be an important effect on cognitive function, but hospital stay may be slightly shorter, although available data are limited. Treatment decisions must weigh the value of an increase in serum sodium concentration against its short-term risks and unknown effects on patient-important outcomes. Evidence for other treatments is largely absent.Further studies assessing standard treatments such as fluid restriction or urea against placebo and one-another would inform practice and are warranted. Given the limited available evidence for patient-important outcomes, any study should include these outcomes in a standardised manner.

show abstract

182 Effect of M0002, a Novel V2 Antagonist on Sodium Levels and Weight Gain Affected by Water Accumulation in Cirrhotic Patients With Ascites

Cited by 5 publications

References 0 publications

Management of ascites in cirrhosis

Management of ascites in cirrhosis

Medical management of ascites

Interventions for chronic non-hypovolaemic hypotonic hyponatraemia

Contact Info

Product

Resources

About